Alpha Tau Medical (DRTS) Net Cash Flow (2021 - 2022)
Alpha Tau Medical (DRTS) posted Net Cash Flow of -$86.3 million for Q2 2022, down 214.92% sequentially from $75.1 million in Q1 2022.
Powered by 
Analysis
Alpha Tau Medical (DRTS) Net Cash Flow (2021 - 2022) Analysis & Trends
Alpha Tau Medical has reported Net Cash Flow for 2 years, with the latest figure at -$86.3 million in Q2 2022.
- Quarterly Net Cash Flow changed N/A year-over-year to -$86.3 million in Q2 2022, while the trailing twelve-month figure through Mar 2023 was -$86.3 million (down 214.92% YoY) and the FY2025 annual result came in at -$1.5 million, down 248.61% from the prior year.
- Net Cash Flow fell to -$86.3 million in Q2 2022 per DRTS's latest filing, from $75.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $75.1 million in Q1 2022 and troughed at -$86.3 million in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Alpha Tau Medical | 1.21 Bn | 1.11 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | -86.31 Mn |
| Mar 31, 2022 | 75.10 Mn |
| Mar 31, 2021 | -3.74 Mn |